NO20004527L - Modulatorer for proteintyrosinfosfataser (PTPaser) - Google Patents

Modulatorer for proteintyrosinfosfataser (PTPaser)

Info

Publication number
NO20004527L
NO20004527L NO20004527A NO20004527A NO20004527L NO 20004527 L NO20004527 L NO 20004527L NO 20004527 A NO20004527 A NO 20004527A NO 20004527 A NO20004527 A NO 20004527A NO 20004527 L NO20004527 L NO 20004527L
Authority
NO
Norway
Prior art keywords
diseases
compounds
ptpases
protein tyrosine
shp
Prior art date
Application number
NO20004527A
Other languages
English (en)
Other versions
NO20004527D0 (no
Inventor
Niels Peter Hundahl Moeller
Henrik Sune Andersen
Lars Fogh Iversen
Ole Hvilsted Olsen
Sven Branner
Daniel Dale Holsworth
Farid Bakir
Luke Milburn Judge
Frank Urban Axe
Todd Kevin Jones
William Charles Ripka
Yu Ge
Roy Teruyuki Uyeda
Original Assignee
Novo Nordisk As
Ontogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK1999/000121 external-priority patent/WO1999046267A1/en
Application filed by Novo Nordisk As, Ontogen Corp filed Critical Novo Nordisk As
Publication of NO20004527D0 publication Critical patent/NO20004527D0/no
Publication of NO20004527L publication Critical patent/NO20004527L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrodes Of Semiconductors (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Bipolar Transistors (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Control Of El Displays (AREA)
  • Indole Compounds (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer nye forbindelser, nye preparater, fremgangsmåter for deres anvendelse, og fremgangsmåter for deres fremstilling, hvor slike forbindelser er farmakologisk anvendbare inhibitorer for proteintyrosinfosfataser (PTPaser), slik som PTP1B, CD45, SHP-1, SHP-2, . PTPa, LAR og HePTP, eller lignende. Forbindelsene kan anvendes ved behand- ling av sukkersyke av type I, sukker- syke av type II, forstyrret glukose- toleranse, insulinresistens, fedme, immundysfunksjoner, inkludert auto- immunitetssykdommer med dysfunksjoner i koagulasjonssystemet, allergiske syk- dommer, inkludert astma, osteoporose, proliferative forstyrrelser, inkludert kreft og psoriasis, sykdommer med redusert eller forøkt syntese eller effekter av veksthormon, sykdommer med redusert eller forøkt syntese av hor- moner eller cytokiner som regulerer frigjørelsen av/eller responsen på veksthormon, sykdommer i hjernen, inkludert Alzheimers sykdom og schizo- freni, og infeksiøse sykdommer.
NO20004527A 1998-03-12 2000-09-11 Modulatorer for proteintyrosinfosfataser (PTPaser) NO20004527L (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DK34498 1998-03-12
DK48098 1998-04-03
DKPA199800938 1998-07-15
DKPA199801385 1998-10-28
DKPA199801612 1998-12-07
PCT/DK1999/000121 WO1999046267A1 (en) 1998-03-12 1999-03-11 Modulators of protein tyrosine phosphatases (ptpases)

Publications (2)

Publication Number Publication Date
NO20004527D0 NO20004527D0 (no) 2000-09-11
NO20004527L true NO20004527L (no) 2000-11-07

Family

ID=27512769

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004527A NO20004527L (no) 1998-03-12 2000-09-11 Modulatorer for proteintyrosinfosfataser (PTPaser)

Country Status (13)

Country Link
EP (1) EP1080095B1 (no)
JP (1) JP2002506072A (no)
KR (1) KR20010041814A (no)
CN (1) CN1300291A (no)
AT (1) ATE308546T1 (no)
AU (1) AU2713599A (no)
BR (1) BR9908726A (no)
CA (1) CA2323493A1 (no)
DE (1) DE69928100D1 (no)
HU (1) HUP0104984A3 (no)
IL (1) IL138319A0 (no)
NO (1) NO20004527L (no)
PL (1) PL342816A1 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE548031T1 (de) 2000-12-18 2012-03-15 Inst Med Molecular Design Inc Inhibitoren gegen die produktion und freisetzung entzündungfördernder zytokine
EP1512396A4 (en) * 2002-06-05 2008-12-31 Inst Med Molecular Design Inc INHIBITORS OF AP-1 AND NFAT ACTIVATION
EP1510207A4 (en) * 2002-06-05 2008-12-31 Inst Med Molecular Design Inc THERAPEUTIC MEDICAMENT AGAINST DIABETES
CN1658872B (zh) 2002-06-06 2010-09-22 株式会社医药分子设计研究所 抗过敏药
KR20110028554A (ko) 2002-06-06 2011-03-18 가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼 Ｏ-치환 히드록시아릴 유도체
SI1753512T1 (sl) * 2004-05-28 2008-12-31 4Sc Ag Tetrahidropiridotiofeni
ES2308504T3 (es) * 2004-06-04 2008-12-01 4Sc Ag Tetrahidropiridotiofenos para su utilizacion en el tratamiento del cancer.
EP1758655A2 (en) * 2004-06-11 2007-03-07 Altana Pharma AG Tetrahydropyridothiophenes for treating hyperproliferative disorders
CN101891680B (zh) * 2004-06-24 2014-10-29 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
JP2008529989A (ja) * 2005-02-09 2008-08-07 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌のような増殖性の疾病の治療用のテトラヒドロピリドチオフェン
JP2008530053A (ja) * 2005-02-11 2008-08-07 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌の治療のための抗増殖性剤としてのテトラヒドロピリドチオフェン
BRPI0616239A2 (pt) * 2005-09-15 2011-06-14 Hoffmann La Roche derivados de Ácido 4-amino-tieno[3,2-c]piridina-7-carboxÍlico, formulaÇço farmacÊutica contendo os mesmos bem como seus usos
CN1939922B (zh) * 2005-09-27 2010-10-13 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3，4-c]吡咯-4，6-二酮衍生物
BR122021013836B1 (pt) * 2009-12-04 2022-05-24 Sunovion Pharmaceuticals, Inc. Composto e seu uso, composição farmacêutica
CN102382076B (zh) * 2010-09-03 2016-08-17 中国医学科学院药物研究所 芳酮和芳酰胺类化合物及其制法和药物用途
CN102838625B (zh) * 2011-06-22 2015-04-15 中国科学院上海药物研究所 四氢吡啶并噻唑类化合物、其制备方法、包含该化合物的药物组合物及其用途
CN104955456B (zh) 2013-01-28 2018-07-03 H.隆德贝克有限公司 作为分拣蛋白抑制剂的n-取代的-5-取代的邻氨甲酰苯甲酸
CN104788424A (zh) * 2015-03-12 2015-07-22 佛山市赛维斯医药科技有限公司 含烟酸酰胺和哌啶结构的ptp1b抑制剂、制备方法及其用途
CN104725306A (zh) * 2015-03-12 2015-06-24 佛山市赛维斯医药科技有限公司 一类含烟酸酰胺结构的ptp1b抑制剂、制备方法及其用途
CN104788425A (zh) * 2015-03-12 2015-07-22 佛山市赛维斯医药科技有限公司 一类含烟酸酰胺和哌啶结构ptp1b抑制剂、制备方法及其用途
CN104725308A (zh) * 2015-03-12 2015-06-24 佛山市赛维斯医药科技有限公司 含烟酸酰胺结构的ptp1b抑制剂、制备方法及其用途
CN104829629B (zh) * 2015-03-26 2017-03-15 天津药物研究院有限公司 含磺酰胺基的四氢噻吩并[2,3‑c]吡啶衍生物、其制备方法和用途
MX2019000980A (es) 2016-07-29 2019-07-04 Sunovion Pharmaceuticals Inc Compuestos y composiciones y usos de los mismos.
WO2018023070A1 (en) 2016-07-29 2018-02-01 Sunovion Pharmaceuticals, Inc. Compounds and compositions and uses thereof
CN116808023A (zh) 2017-02-16 2023-09-29 桑诺维恩药品公司 治疗精神分裂症的方法
WO2019028165A1 (en) 2017-08-02 2019-02-07 Sunovion Pharmaceuticals Inc. ISOCHROMAN COMPOUNDS AND USES THEREOF
EA202091945A1 (ru) 2018-02-16 2021-01-18 Суновион Фармасьютикалз Инк. Соли, кристаллические формы и способы их получения
JP2022525169A (ja) 2019-03-14 2022-05-11 サノビオン ファーマシューティカルズ インク イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物
KR20230003503A (ko) 2020-04-14 2023-01-06 선오비온 파마슈티컬스 인코포레이티드 신경학적 및 정신의학적 장애의 치료를 위한 (S)-(4,5-디히드로-7H-티에노[2,3-c]피란-7-일)-N-메틸메탄아민

Also Published As

Publication number Publication date
NO20004527D0 (no) 2000-09-11
KR20010041814A (ko) 2001-05-25
AU2713599A (en) 1999-09-27
EP1080095A1 (en) 2001-03-07
HUP0104984A3 (en) 2003-07-28
ATE308546T1 (de) 2005-11-15
CA2323493A1 (en) 1999-09-16
PL342816A1 (en) 2001-07-02
CN1300291A (zh) 2001-06-20
DE69928100D1 (de) 2005-12-08
JP2002506072A (ja) 2002-02-26
EP1080095B1 (en) 2005-11-02
BR9908726A (pt) 2000-11-21
HUP0104984A2 (hu) 2002-04-29
IL138319A0 (en) 2001-10-31

Similar Documents

Publication Publication Date Title
NO20004527L (no) Modulatorer for proteintyrosinfosfataser (PTPaser)
Yoon et al. Anti-inflammatory effect of quercetin in a whole orbital tissue culture of Graves' orbitopathy
Cheng et al. Tumor necrosis factors protect neurons against metabolic-excitotoxic insults and promote maintenance of calcium homeostasis
Kalina et al. IL-18 activates STAT3 in the natural killer cell line 92, augments cytotoxic activity, and mediates IFN-γ production by the stress kinase p38 and by the extracellular regulated kinases p44erk-1 and p42erk-21
Tezel TNF-α signaling in glaucomatous neurodegeneration
Tang et al. Wnt-1 promotes neuronal differentiation and inhibits gliogenesis in P19 cells
Majka et al. Regulation of matrix metalloproteinase expression by tumor necrosis factor in a murine model of retinal neovascularization
Su et al. Electroacupuncture reduces the expression of proinflammatory cytokines in inflamed skin tissues through activation of cannabinoid CB 2 receptors
EP1423428A4 (en) ANTIBODIES BLOCKING THE ACTIVATION OF A TYROSINE KINASE PROTEIN ACTIVATED RECEPTOR, SCREENING METHODS AND USES THEREOF
Huh et al. Formononetin attenuates osteoclastogenesis via suppressing the RANKL-induced activation of NF-κB, c-Fos, and nuclear factor of activated T-cells cytoplasmic 1 signaling pathway
IL170866A (en) A low-fouling liquid preparation containing antibody against ige
ATE348828T1 (de) Beta-carbolin-derivate als ptp-inhibitoren
Li et al. Hedgehog signaling is involved in the BMP9-induced osteogenic differentiation of mesenchymal stem cells Retraction in/10.3892/ijmm. 2023.5233
Calkins et al. Differential effects of recombinant interleukin-1α and β on Leydig cell function
BRPI0407446A (pt) Anticorpos para c-met para o tratamento de cânceres
Chowdhury et al. Dynamic compression counteracts IL-1β induced inducible nitric oxide synthase and cyclo-oxygenase-2 expression in chondrocyte/agarose constructs
ATE475716T1 (de) Zusammenstellungen zur behandlung von neurodegenerativen erkrankungen
Utsunomiya et al. Fruit-juice concentrate of Asian plum inhibits growth signals of vascular smooth muscle cells induced by angiotensin II
Fu et al. Interleukin-18-induced inflammatory responses in synoviocytes and chondrocytes from osteoarthritic patients
Liu et al. Tenuifoliside A promotes neurite outgrowth in PC12 cells via the PI3K/AKT and MEK/ERK/CREB signaling pathways
Kim et al. Chondroprotective effect of curcumin and lecithin complex in human chondrocytes stimulated by IL-1β via an anti-inflammatory mechanism
Zhu et al. Aucubin suppresses Titanium particles‑mediated apoptosis of MC3T3‑E1 cells and facilitates osteogenesis by affecting the BMP2/Smads/RunX2 signaling pathway
Faghih et al. Directed differentiation of human adipose tissue-derived stem cells to dopaminergic neurons in low-serum and serum-free conditions
Zhou et al. TRESK gene recombinant adenovirus vector inhibits capsaicin-mediated substance P release from cultured rat dorsal root ganglion neurons
Hošek et al. Effect of diplacone on LPS-induced inflammatory gene expression in macrophages